BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18945750)

  • 1. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
    López-Guerra M; Trigueros-Motos L; Molina-Arcas M; Villamor N; Casado FJ; Montserrat E; Campo E; Colomer D; Pastor-Anglada M
    Haematologica; 2008 Dec; 93(12):1843-51. PubMed ID: 18945750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
    Molina-Arcas M; Marcé S; Villamor N; Huber-Ruano I; Casado FJ; Bellosillo B; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
    Leukemia; 2005 Jan; 19(1):64-8. PubMed ID: 15510196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
    Hong M; Xia Y; Zhu Y; Zhao HH; Zhu H; Xie Y; Fan L; Wang L; Miao KR; Yu H; Miao YQ; Wu W; Zhu HY; Chen YY; Xu W; Qian SX; Li JY
    Leuk Res; 2016 Nov; 50():72-77. PubMed ID: 27693855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
    Mackey JR; Galmarini CM; Graham KA; Joy AA; Delmer A; Dabbagh L; Glubrecht D; Jewell LD; Lai R; Lang T; Hanson J; Young JD; Merle-Béral H; Binet JL; Cass CE; Dumontet C
    Blood; 2005 Jan; 105(2):767-74. PubMed ID: 15454483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.
    Fernández-Calotti PX; Lopez-Guerra M; Colomer D; Pastor-Anglada M
    Haematologica; 2012 Jun; 97(6):943-51. PubMed ID: 22180426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.
    Molina-Arcas M; Bellosillo B; Casado FJ; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
    Blood; 2003 Mar; 101(6):2328-34. PubMed ID: 12411296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
    Fernández Calotti P; Galmarini CM; Cañones C; Gamberale R; Saénz D; Avalos JS; Chianelli M; Rosenstein R; Giordano M
    Biochem Pharmacol; 2008 Feb; 75(4):857-65. PubMed ID: 18078872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
    Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
    Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
    Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
    Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
    Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
    Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
    Yao L; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):821-4. PubMed ID: 20561458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
    Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
    Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
    Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
    Turgut B; Vural O; Pala FS; Pamuk GE; Tabakcioğlu K; Demir M; Ongören S; Soysal T; Algüneş C
    Leuk Lymphoma; 2007 Feb; 48(2):311-20. PubMed ID: 17325891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.